| 1. |
A phase 3 trial of bendamustine/rituximab for relapsed or refractory diffuse large b-cell lymphoma （口頭発表，一般） 2021/09
|
| 2. |
Blastic plasmacytoid dendritic cell neoplasm lacking CD4 expression （ポスター，一般） 2021/09
|
| 3. |
Co-expression of chromosomal abnormalities predict poor responsibility for EPD treatment （ポスター，一般） 2021/09
|
| 4. |
Long term prognosis of patient with chronic DIC who has ITP （ポスター，一般） 2021/09
|
| 5. |
Two cases of lymphoplasmacytic lymphoma presenting lymphomatous infiltration of the kidneys （ポスター，一般） 2021/09
|
| 6. |
免疫性血小板減少症の経過中に顕在化しTKI 治療により血小板の増加が得られた慢性骨髄性白血病 （口頭発表，一般） 2021/03
|
| 7. |
Carfilzomib regimen in patients with multiple myeloma intolerable or relapsed to VRD induction （口頭発表，一般） 2020/10
|
| 8. |
Efficacy and safety of bendamustine in elderly patients with R/R low-grade B-cell lymphoma and MCL （口頭発表，一般） 2020/10
|
| 9. |
Final analysis of a phase 2 study of ixazomib plus LenDex in Japanese RRMM patients （口頭発表，一般） 2020/10
|
| 10. |
KEYNOTE-204: phase 3 study of pembrolizumab vs brentuximab vedotin in R/R classical Hodgkin lymphoma （口頭発表，一般） 2020/10
|
| 11. |
Phase 2 study of E7777 on relapsed or refractory, peripheral and cutaneous T-cell lymphoma in Japan （口頭発表，一般） 2020/10
|
| 12. |
Phase II study of tirabrutinib in Japanese patients with Waldenstrom's macroglobulinemia （口頭発表，一般） 2020/10
|
| 13. |
Polatuzumab vedotin with bendamustine and rituximab in r/r DLBCL (P-DRIVE): A phase 2 study in Japan （口頭発表，一般） 2020/10
|
| 14. |
Transformed follicular lymphoma in relation with rituximab maintenance and chromosome 8 aberrations （口頭発表，一般） 2020/10
|
|
5件表示
|
|
全件表示(14件)
|